SCHEMBL683597

SCHEMBL683597

CC(C)(C)Nc1ccccc1N=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.41
SIGMAR1 Q99720 5/20 0.35
GRIN2D O15399 3/20 0.35
GRIN3B O60391 3/20 0.35
GRIN1 Q05586 3/20 0.35
GRIN2A Q12879 3/20 0.35
GRIN2B Q13224 3/20 0.35
GRIN2C Q14957 3/20 0.35
GRIN3A Q8TCU5 3/20 0.35
ATM Q13315 1/20 0.34
GAA P10253 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CETP P11597 1/20 0.32
KDM4E B2RXH2 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
MAPT P10636 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
POLB P06746 1/20 0.31
ALDH1A1 P00352 1/20 0.31
ALOX12 P18054 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25642562 0.78 IDO1 (0.41) IDO1SIGMAR1GRIN2DGRIN3BGRIN1
SCHEMBL6251669 0.78 IDO1 (0.52) IDO1ATMCETPKDM4ETDP1
SCHEMBL29881429 0.78 IDO1 (0.52) IDO1ATMCETPKDM4ETDP1
SCHEMBL8268456 0.77 KDM4E (0.43) IDO1SIGMAR1GRIN2DGRIN3BGRIN1
SCHEMBL24916381 0.77 IDO1 (0.40) IDO1SIGMAR1GRIN2DGRIN3BGRIN1
SCHEMBL13365306 0.75 PLK1 (0.41) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL11912167 0.73 CA12 (0.43) IDO1SIGMAR1GRIN2DGRIN3BGRIN1
SCHEMBL27809964 0.73 GAA (0.32) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL105074 0.73 HTT (0.39) IDO1SIGMAR1GRIN2DGRIN3BGRIN1
SCHEMBL27810015 0.73 NPC1 (0.31) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 IDO1 2728/4885SIGMAR1 455/4885GRIN2D 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.